English
+38 068 889 89 89
00380930552240 (باللغة العربية)
00380930552240 (باللغة العربية)
+38 044 223 28 95
Contact us

Treatment of type II diabetes mellitus, moderate course

Female patient Kh.V.N., born in 1944, stayed at EmCell Clinic.

Diagnosis:
Diabetes mellitus type 2, moderate form, subcompensation; climacteric syndrome.

On admittance, the patient complained of weakness, xerostomia, headache, vertigo, decreased working capacity, presence of hypertensive crises with shivering, petechiae, palpitation, sweating, frequent and abundant urination at the end of each attack.

The above complaints were noted during two years since the disturbance of the menstrual cycle appeared. A menopause was noted during one year. Insulin-independent diabetes mellitus was detected year ago. At first, the patient kept to a diet, then she started glipisid (daily dosage of up to 20 mg); due to poor compensation, it was changed for glibenclamid (daily dosage of 10 mg). During the last month, the patient has been taking propranolol (daily dosage of 60 mg).

On admittance, glycemic profile was 8.4–9.3–11.5–7.4 mmole/l; glucosuria, 10 g/l. Routine clinical laboratory test results (average blood tests, urinalyses, chemistry) are within the normal values. ECG: synus rhythm. Signs of moderate changes of myocardium.

On examination: Skin and exposed mucous coats are clean. Pulse rate is 74 beats/min, rhythmic. Arterial pressure is 130/90 mm Hg. Cardiac sounds are clear, with right melody. Lungs are clear. The abdomen is soft and painless in palpation. Liver: +1 cm from right medioclavicular line, soft and painless edge. Spleen: not enlarged. Large bowel unremarkable.

The patient was treated with medicinal preparation based on fetal cell suspensions (sample 3038C372; amount of cells, 38.7x106/ml; CFU-GM, 31x103; CFU-GEMM, 17.3x103; CD34+, 6.2x106/ml; total volume 2.0 ml). Method of administration was intravenous, dropwise.

The patient tolerated infusion without any complications and felt improvement from the very first day: rapid, without headache attacks or palpitation. During the first week, an increase of glycemia was observed in the course of a day. After 2 weeks, a compensation was achieved with the use of the previous sugar-decreasing therapy (glibenclamid, 10 mg/day). After 1 month, the daily dosage of preparation was decreased, with close glycemic control, down to 5 mg. During subsequent 7 months of observation, a stable compensation of carbohydrate metabolismwas noted (glycemia during the day, 5.4–10.2 mmole/l, aglucosuria), normalization of arterial pressure under discontinuation of hypoglycemic and hypotensive preparations. Neurovascular crises actually did not occur.

Fetal stem cells treatment results depend on: disease's severity, age of the patient, adherence for the medications and regime. Treatment results, presented on this site, are individual for each clinical case.